Evan Seigerman Analyst PerformanceAnalyst at BMO Capital MarketsEvan Seigerman is a stock analyst at BMO Capital Markets in the medical sector, covering 13 publicly traded companies. Over the past year, Evan Seigerman has issued 18 stock ratings, including buy, hold, and sell recommendations. While full access to Evan Seigerman's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Evan Seigerman's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings56 Last 6 YearsBuy Recommendations55.77% 29 Buy RatingsCompanies Covered13 Unique Companies Ratings Distribution52RatingsDistribution of strong buy, buy, hold, and sell ratings by Evan Seigerman.RatingPercentageCount Strong Buy0.0%0 ratings Buy55.8%29 ratings Hold34.6%18 ratings Sell9.6%5 ratingsOut of 52 total stock ratings issued by Evan Seigerman at BMO Capital Markets, the majority (55.8%) have been Buy recommendations, followed by 34.6% Hold and 9.6% Sell.Best & Worst CallsBest Call000.0%GILDFeb 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%REGNMay 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ84.6% of companies on NASDAQ11 companiesNYSE15.4% of companies on NYSE2 companiesEvan Seigerman, an analyst at BMO Capital Markets, currently covers 13 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical13 companies100.0%Evan Seigerman of BMO Capital Markets specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE9 companies69.2%LARGE CAP PHARMA2 companies15.4%MED - DRUGS1 company7.7%PHARMACEUTICAL PREPARATIONS1 company7.7% Evan Seigerman's Ratings History at BMO Capital Markets Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsGPCRStructure Therapeutics3/17/2026Set Price Target$55.92$145.00Outperform$0.0000.00% ROINBIXNeurocrine Biosciences2/12/2026Lower Price Target$125.89$140.00Market Perform$0.0000.00% ROIBIIBBiogen2/6/2026Boost Price Target$201.69$196.00Market Perform$0.0000.00% ROINVONovo Nordisk A/S2/5/2026Reiterated Rating$44.37Market Perform$0.0000.00% ROINVONovo Nordisk A/S2/5/2026Set Price Target$47.18$45.00$0.0000.00% ROILLYEli Lilly and Company2/5/2026Reiterated Rating$1,107.13$1,300.00Outperform$0.0000.00% ROINVONovo Nordisk A/S1/26/2026Set Price Target$63.60$57.00$0.0000.00% ROILLYEli Lilly and Company1/14/2026Reiterated Rating$1,066.49Outperform$0.0000.00% ROITERNTerns Pharmaceuticals12/9/2025Boost Price Target$40.23$54.00Outperform$0.0000.00% ROILLYEli Lilly and Company12/4/2025Set Price Target$1,033.00$1,200.00$0.0000.00% ROIAMGNAmgen12/3/2025Boost Price Target$338.36$372.00Outperform$0.0000.00% ROILLYEli Lilly and Company12/2/2025Boost Price Target$1,059.14$1,100.00Outperform$0.0000.00% ROITERNTerns Pharmaceuticals11/18/2025Boost Price Target$26.82$30.00Outperform$0.0000.00% ROILLYEli Lilly and Company11/6/2025Boost Price Target$927.48$1,100.00Outperform$0.0000.00% ROITERNTerns Pharmaceuticals11/3/2025Boost Price Target$14.03$22.00Outperform$0.0000.00% ROINVONovo Nordisk A/S10/14/2025Reiterated Rating$57.51$55.00Market Perform$0.0000.00% ROIVRTXVertex Pharmaceuticals8/5/2025Set Price Target$472.27$530.00Outperform$0.0000.00% ROIINCYIncyte7/30/2025Reiterated Rating$78.05$60.00Underperform$0.0000.00% ROIIRONDisc Medicine5/12/2025Boost Price Target$47.07$120.00Outperform$00.0000.00% ROINBIXNeurocrine Biosciences5/6/2025Boost Price Target$125.03$115.00Market Perform$000.0000.00% ROIGILDGilead Sciences2/12/2025Boost Price Target$103.85$115.00Outperform$000.0000.00% ROIVRTXVertex Pharmaceuticals1/31/2025Set Price Target$484.24$545.00$000.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenWeiss RatingsUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel Nicolaus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
